Acute and chronic respiratory failure are a significant source of pediatric morbidity and mortality. Current respiratory support options used to bridge children to lung recovery or transplantation typically render them bedridden and can worsen long-term patient outcomes. The Pittsburgh Pediatric Ambulatory Lung (P-PAL) is a wearable pediatric blood pump and oxygenator (0.3 m 2 surface area) integrated into a single compact unit that enables patient ambulation. The P-PAL is intended for long-term use and designed to provide up to 90% of respiratory support in children weighing 5-25 kg. Computational fluid dynamics and numerical gas exchange modeling were used to design the P-PAL and predict its performance. A P-PAL prototype was then used to obtain pressure versus flow curves at various impeller rotation rates using a blood analog fluid. In vitro oxygen exchange rates were obtained in blood in accordance with ISO standard 7199. The normalized index of hemolysis (NIH) was measured over a 6 hour period at blood flow rates of 1 and 2.5 L/min. The P-PAL provided blood flows of 1-2.5 L/min against the pressure drop associated with its intended-use pediatric cannulas. The oxygen exchange rate reached a maximum of 108 ml/min at a blood flow rate of 2.5 L/min and met our respiratory support design target. Device-induced hemolysis was low with NIH values of 0.022-0.027 g/100 L in the intended blood flow rate range. In conclusion, the current P-PAL design met our pumping, oxygenation, and hemolysis specifications and has the potential to improve treatment for pediatric respiratory failure. ASAIO Journal 2018; 64:806-811.
source of morbidity and mortality within the pediatric population. Although acute lung injury (ALI) is less prevalent in children than adults, ALI accounts for up to 30% of deaths within some pediatric intensive care units. 1 The incidence of ALI is also suspected to be underestimated in the literature due to alternative diagnoses. 2 In regard to chronic lung disease, lung and lung-heart transplants have become increasingly more frequent for children with end-stage cystic fibrosis, pulmonary hypertension, and pulmonary fibrosis. 3 The International Society for Heart and Lung Transplantation Registry reports that from 1986 to 2013, 2,091 lung and 689 heart-lung transplants were performed worldwide in pediatric patients with these numbers continuing to rise in recent years. 4 This datum also likely underestimates the true number of transplants due to those procedures not reported to the Registry. The duration that pediatric patients are on a waiting list before receiving a donor lung can be less than a month to a matter of years. Between 2009 and 2011, approximately 80% of patients waited more than 1 month with the majority of those children receiving a transplant in 1-6 months. 5 Mechanical ventilation (MV) and extracorporeal membrane oxygenation (ECMO) are currently used to support children with lung failure as a bridge to lung recovery or transplantation. Multiple studies, however, have demonstrated poor posttransplant outcomes related to the use of these procedures on children awaiting lung transplantation. 6, 7 Consequently, many transplant centers consider the pre-transplant use of MV and ECMO a contraindication to lung transplantation. 3, 7 Longterm use of MV can result in barotrauma and volutrauma. 8 The successful use of conventional ECMO can be hindered by its numerous system components and generally cumbersome nature. In addition, both treatments typically require immobilization of the patient, which often leads to a progressive deconditioning that can increase post-transplant morbidity and mortality. 9, 10 Ambulation and active rehabilitation during the pre-transplant period, however, have been shown to counteract such deconditioning and improve patient outcomes. 11, 12 Thus, there is a clear unmet need for development of a more efficient and smaller pediatric respiratory assist device that allows patient ambulation.
Here we describe the initial development of the Pittsburgh Pediatric Ambulatory Lung (P-PAL). The P-PAL integrates a centrifugal pump with a highly efficient oxygenating hollow fiber membrane (HFM) bundle into a single compact unit that is meant to be wearable and allow for ambulation. The P-PAL is proposed for longer-term use (1-3 months without device exchange) in children weighing 5-25 kg and intended to replace MV or conventional ECMO as a bridge to transplant or recovery during lung failure. During use of the P-PAL, blood flow is redirected from the patient to the P-PAL via a venous cannula, driven through the gas-exchanging HFM bundle by the integrated pump, and then returned to the patient via an arterial cannula. Primary performance specifications were to provide up to 90% of respiratory support while pumping blood 1-2.5 L/min and maintaining low device-induced hemolysis. Minimization of the HFM surface area and overall device size were also a primary focus to both minimize blood-contacting surfaces and allow for patient mobility. Computational fluid dynamics (CFD) and numerical gas exchange modeling were used to design the P-PAL as well as to analyze its performance. A P-PAL prototype was fabricated and used to characterize in vitro pumping and oxygenation capabilities over the intended operating conditions. Six hour hemolysis evaluations were also conducted to assess the level of blood damage induced by the device.
Materials and Methods

P-PAL Design and Fabrication
A schematic and picture of the P-PAL prototype are shown in Figure 1 . The centrifugal pump utilizes an enclosed impeller to draw blood in through the venous cannula and drive flow through the HFM bundle and arterial cannula. The P-PAL housing and impeller were modeled in SolidWorks CAD software (Dassault Systèmes, SolidWorks Corp., Waltham, MA) and machined from clear acrylic and polycarbonate, respectively. After machining, the housing surfaces were polished to a translucent, glass-like finish, whereas the impeller surfaces were vapor polished. Permanent magnets were embedded in the impeller to enable magnetic coupling with an external motor that drives impeller rotation. The two-pivot bearing system is composed of ceramic pivots at either end of the impeller shaft that are supported by ultra-high molecular weight polyethylene cups. Similar to an adult pump-oxygenator currently under development by our group, 13 . The bundle was manufactured from commercially available polymethylpentene hollow fiber sheets (OXYPLUS, 44 fibers per inch, Membrana GmbH, Wuppertal, Germany) using previously described methods. 13 Briefly, circular fiber sheets were stacked alternatingly at a 14° crossing angle and potted using a polyurethane adhesive (Vertellus Performance Materials Inc., Greensboro, NC). The current P-PAL prototype has a total weight of approximately 2.5 lb, but this weight will be significantly reduced once the P-PAL design is validated and fabrication moves to injection molded components.
Modeling
Oxygen transfer in the P-PAL was modeled using a previously developed mass transfer correlation. 15 The mass balance for oxygen transfer in a cylindrical HFM bundle is given by Equation 1.
where Q is the volumetric blood flow rate through the bundle (ml/s), C O 2 is the concentration of oxygen in the blood (ml O 2 / ml blood), R is the bundle radius (cm), k is the mass transfer coefficient [ml O 2 /(cm 2 ·s·mm Hg)], a v is the surface area-tovolume ratio of the bundle (cm 2 /cm 3 ), ∆P O 2 is the oxygen partial pressure difference between the blood and gas sides of the fiber (mm Hg), and z is the axial coordinate (cm). C O 2 accounts for both dissolved and chemically bound oxygen in the blood and is given by Equation 2.
where α O 2 is the solubility of oxygen in blood [3E-5 ml O 2 / (ml blood·mm Hg)], P O 2 is the partial pressure of oxygen in the blood (mm Hg), C T is the binding capacity of saturated blood (0.167 ml O 2 /ml blood), and S O 2 is the fractional blood oxygen saturation. Substituting Equation 2 into Equation 1 results in a 
is a previously used 15 effective diffusivity for oxygen in blood (cm 2 /s) and accounts for chemically bound oxygen. The differential equation resulting from Equations 1-4 was solved in MATLAB (MathWorks, Natick, MA) using the built-in ordinary differential equation solver based on the Runge-Kutta method. Oxygen transfer rates were calculated for the P-PAL at blood flow rates of 1-2.5 L/min to determine the required HFM surface area to meet oxygenation requirements.
Blood flow velocities and pressures within the P-PAL were modeled via laminar CFD analysis performed using ANSYS Fluent v17 (ANSYS, Canonsburg, PA). Blood was treated as a homogeneous incompressible fluid of density 1050 kg/m 3 and constant viscosity of 3.5 cP. The fiber bundle was modeled as porous media with a uniform viscous resistance 17 of 1E9 1/ m 2 and a fluid porosity of 0.5. The CFD mesh consisted of 4M tetrahedral cells, and impeller motion was implemented using a frozen relative motion frame of reference.
Hydrodynamic Performance
In vitro pump performance of the P-PAL was evaluated using a carboxymethyl cellulose (CMC) sodium salt (Sigma Aldrich, St. Louis, MO) solution (8.5 g/L) as the working fluid. The CMC solution was prepared to have a viscosity of 3.5 cP when heated to 37°C and the viscosity verified using a capillary viscometer (Cannon Instrument Company, State College, PA). The experimental circuit consisted of the P-PAL connected to an 800 ml compliant blood reservoir (Medtronic, Minneapolis, MN). The reservoir was submerged within a heated water bath during testing to maintain the temperature of the working fluid at 37 ± 2°C. Pressures at the inlet and outlet of the P-PAL were measured in triplicate using a Honeywell 143 PC03D transducer (Honeywell International Inc., Morris Plains, NJ) at flow rates of 0-3 L/ min and impeller rotation rates of 1000, 1200, 1400, 1600, and 1800 RPM. Flow rate was measured using an ultrasonic flow probe (Transonic Systems Inc., Ithaca, NY) and varied at each rotation rate using a Hoffman clamp distal to the device.
During clinical use the, P-PAL is intended to be used with a 14 Fr DLP straight tip arterial cannula (#75014, Medtronic, Minneapolis, MN) and 18 Fr DLP malleable venous cannula (#68118, Medtronic, Minneapolis, MN). The pressure drop of those cannulas was measured using methods similar to those described above. Measurements were made at flow rates of 0-3 L/min with flow being driven by a Biomedicus BP 80-X pump (Medtronic, Minneapolis, MN).
In Vitro Oxygenation
In vitro oxygen exchange rates were measured in accordance with ISO standard 7199 using a previously described experimental circuit 13 and bovine or porcine blood collected from a local slaughterhouse. Before use, blood was filtered (40 µm filter, Pall Biomedical Inc., Fajardo, PR) and treated with heparin (15 IU/ml) and gentamicin (0.1 mg/ml). Blood was first preconditioned to venous conditions (O 2 saturation = 65% ± 5%, pCO 2 = 45 ± 5 mm Hg) via recirculation through a Medtronic Affinity NT oxygenator (Medtronic, Minneapolis, MN). Once venous blood conditions were achieved, sweep gas to the Affinity oxygenator was discontinued and tubing was clamped to produce single-pass blood flow through the P-PAL for oxygen exchange rate measurements. Blood temperature was maintained at 37 ± 2°C throughout the experiment via a Polyscience 210 heater (Polyscience Inc., Niles, IL) connected to the heat exchanger of the Affinity oxygenator. P-PAL oxygen exchange rates were evaluated at blood flow rates from 1 to 2.5 L/min with impeller rotation rates of 1100-1700 RPM to match operating conditions predicted from pump testing. A Hoffman clamp immediately distal to the P-PAL outlet was used to achieve specified flow rates, which were measured via an ultrasonic flow probe. Pure oxygen was used as the sweep gas and maintained at a constant gas flow rate of 6 L/min using a GR series mass flow controller (Fathom Technologies, Georgetown, TX). Blood samples were taken at the inlet and outlet of the test device and analyzed using a RAPIDPoint 405 blood gas analyzer with co-oximetry (Siemens Healthcare Diagnostics Inc., Tarrytown, NY). Six repeated measurements were taken for each condition over the course of two independent experiments. Oxygen exchange rates were calculated from inlet and outlet oxygen partial pressures and saturations using Equation 5 .
where V O 2 is the oxygen exchange rate (ml/min), Q is the blood flow rate (L/min), α O 2 is the solubility of oxygen in blood [3E-
− is the oxygen partial pressure difference across the device (mm Hg), C t is the hemoglobin binding capacity (1.34 ml O 2 /g), Hgb is the hemoglobin concentration (g/dl), and S S − is the fractional oxygen saturation difference across the device.
In Vitro Hemolysis
Blood damage was evaluated at flow rates of 1 and 2.5 L/min in accordance with ASTM F1841-97 using bovine blood collected from a local slaughterhouse. After collection, blood was filtered and treated as previously specified for oxygenation testing. The P-PAL was evaluated in parallel with a control circuit utilizing a Lilliput 2 oxygenator (Sorin Group, Mirandola, Italy) and either a PediMag (used at 1 L/min) or CentriMag (used at 2.5 L/min) blood pump (Thoratec, Pleasanton, CA). Evaluation was performed using a continuous flow circuit consisting of the test device (P-PAL or control) connected to an 800 ml compliant blood reservoir. The compliant reservoir was submerged within a heated water bath during testing to maintain a blood temperature of 37 ± 2°C. A Hoffman clamp distal to the device was used to adjust afterload to achieve a pressure differential of 100 mm Hg across the device. For each operating condition evaluated, blood (hematocrit = 30%) was circulated for a period of 6 hours during which blood samples were collected every 30 minutes. Hematocrit and plasma free hemoglobin measurements were taken for each sample and used to calculate a normalized index of hemolysis (NIH). Details regarding measurement techniques and NIH calculation have been previously published. 18 Three independent trials were conducted for each condition evaluated.
Statistics
SPSS 22 (IBM Corporation, Armonk, NY) was used to perform statistical analysis. A two-way ANOVA was used to determine the significance of the effects of device type and flow rate on NIH. All error bars in presented figures represent standard deviations.
Results
CFD Analyses
Typical CFD results shown in Figure 2 demonstrate adequate pressure generation and uniform flow distribution throughout the bundle. Generated pressure heads predicted by CFD were 88 mm Hg for 1100 RPM, 1 L/min and 196 mm Hg for 1700 RPM, 2.5 L/min. The maximum shear stress in the device for these operating conditions was located on the impeller surfaces and was less than 200 Pa. Flow through the impeller channels was shown to have uniform distribution and exhibited no flow separation. For both operating conditions evaluated, the device was remarkably free of flow stasis and deleterious flow recirculation.
Hydrodynamic Performance
The pressure head generated by the P-PAL as a function of flow rate for impeller rotation rates varying from 1000 to 1800 RPM is shown in Figure 3. Figure 3 also shows the pressure requirements for operating the P-PAL. The pressure requirements are the sum of the pressure drop of the intended-use cannulas and the physiologic pressure differential of the points of cannulation. Right atrium (anticipated position of venous cannula) and pulmonary artery (anticipated position of arterial cannula) pressures of 0 and 50 mm Hg, respectively, were assumed. The P-PAL achieved the targeted flow rates of 1-2.5 L/min at impeller rotation rates between 1100 and 1700 RPM.
In Vitro and Modeled Oxygenation
Measured in vitro oxygen exchange rates as well as those predicted by the model are shown in Figure 4 . Measured oxygen exchange increased with increasing blood flow rate and reached a maximum of 108 ml/min at a blood flow rate of 2.5 L/min. At 2.5 L/min the P-PAL met the oxygenation design target of 106 ml/min, which is approximately 90% of the oxygenation needs for a 25 kg child (based off of body surface area estimated via the Mosteller formula 19 ).
In Vitro Hemolysis
The increase in plasma free hemoglobin over the 6 hour period of measurement exhibited a strong linear trend for all conditions with an average R 2 value of 0.91 among all trials (results not shown). The calculated NIH values for the P-PAL and control circuit are shown in Figure 5 . The NIH was similar between the P-PAL and control circuit with statistical analysis showing no significant effect of device type on NIH.
Discussion
Current treatment options for pediatric lung failure are limited and may contribute to patient morbidity and mortality via their need for patient immobilization. 9, 10 To address this need, our group has begun development of the P-PAL. The P-PAL is a compact, wearable pediatric artificial lung designed to provide long-term respiratory support while enabling patient mobility. A functional P-PAL prototype was fabricated and used to perform a comprehensive benchtop evaluation. In vitro testing of the P-PAL demonstrated that the device is able to meet all specified performance targets.
MV and conventional ECMO are currently used to bridge children with lung failure to recovery or transplantation, but neither option is ideal for long-term support. Such treatments typically leave children bedridden and can often increase morbidity and mortality. 9 Physical therapy has been shown to be beneficial for patients on long-term respiratory support, 11, 12 but no current clinical devices readily allow for ambulation. Once implemented clinically, the P-PAL will have the potential to improve treatment for children on respiratory support.
The P-PAL achieved the required pressure head generation predicted for in vivo conditions at flow rates up to 2.5 L/min. The physiologic pressures assumed in determining the required pressure head represent estimates for children with severe pulmonary hypertension. Thus, the P-PAL is capable of providing the necessary blood flow rates in even the most critically ill pediatric lung failure patients. Pressure heads predicted from CFD correlated well with in vitro testing with a maximum percent error of 2%. Based on flow uniformity from CFD modeling, good surface washing characteristics (i.e., low thrombogenicity potentials) are predicted throughout the device for both operating conditions evaluated.
Oxygenation performance is considered to be the most important gas exchange parameter for the P-PAL. In vivo studies of oxygenators with similar intended blood flow rates have shown the need to introduce CO 2 into the sweep gas to limit its removal and avoid hypocapnia. 14, 20, 21 Thus, oxygen transfer rate was the focus of gas exchange evaluation in this study. The P-PAL met targeted oxygenation specifications at the appropriate blood flow rates. The estimated cardiac output of the intended patient population ranges from 1.3 L/min (5 kg child) to 4.3 L/min (25 kg child). 22 Estimated oxygen uptake for the same patients ranges from 35 ml/ min (5 kg child) to 118 ml/min (25 kg child). 19 Therefore, the targeted 90% of respiratory support is approximately 32 and 106 ml/min for a 5 kg and 25 kg child, respectively. Oxygenation results have demonstrated that the P-PAL is able to achieve these oxygen exchange rates at blood flow rates below the corresponding estimated cardiac outputs. Measured oxygen exchange rates were in good agreement with those predicted from numerical modeling with a maximum percent of error of 9%.
The P-PAL also maintained a low degree of blood damage over the course of 6 hours of continuous operation. P-PAL NIH values were not statistically different from those for the control circuit, which utilized a comparable nonintegrated pump/ oxygenator combination currently in clinical use. Additionally, P-PAL NIH values were approximately 30-65% lower than those previously published for the only similar device in development, the PediPL, 23 over the intended blood flow rates. The maximum shear stress predicted by CFD was less than that associated with significant hemolysis 24 and thus correlated well with the low in vitro hemolysis measurements.
While maintaining similarly low blood damage relative to currently used devices, the P-PAL exhibited high oxygenation efficiency. The maximum blood flow rate for which oxygenation data are available for a wide array of clinically used pediatric devices is 2 L/min. At this blood flow rate, currently used pediatric oxygenators have oxygenation efficiencies of approximately 140-240 ml/min/m 2 (as specified by manufacturer literature, see Supplemental Materials, Supplemental Digital Content, http://links.lww.com/ASAIO/A222). The oxygenation efficiency of the P-PAL at the same flow rate is 310 ml/min/m 2 . This efficiency is comparable to that of the PediPL (approximately 345 ml/min/m 2 at 2 L/min blood flow rate). 23 A high gas exchange efficiency is important because it allows targeted oxygenation rates to be achieved with a smaller HFM bundle. This in turn enables the device to have a minimized blood-contacting surface area and overall device size.
The high oxygenation efficiency of the P-PAL stems primarily from its HFM bundle geometry. The P-PAL HFM bundle is composed of stacked, circular layers of fibers, resulting in a cylindrical bundle with a small cross-sectional area. During use of the P-PAL, blood flows axially along the cylinder and normal to the axis of the fibers (see Figure 1) . Previous modeling and in vitro work has shown that such an HFM bundle design achieves exceptionally high gas transfer efficiencies by maximizing the velocity of blood across the fibers. 13 The large relative velocity between the blood and fibers results in a reduction of the diffusional boundary layer at the fiber surface (the primary impediment to the gas transfer process 25 ). A distinct difference between the P-PAL and PediPL is the manner in which the pump impeller is supported. The PediPL employs the magnetic levitation motor and control system of the CentriMag blood pump, 23 whereas the P-PAL utilizes a two-pivot ceramic bearing system. The use of a magnetically levitated impeller theoretically reduces shear stress on the blood, 26 but can also add complexity to the device and drive system. 27 A recent study comparing the use of two similar blood pumps with and without a magnetically levitated impeller during ECMO found no difference in patient outcomes. 28 In conclusion, the P-PAL is a compact, fully integrated blood pump and oxygenator designed to provide adequate respiratory support for children up to 25 kg while enabling patient mobility. In vitro evaluation of the P-PAL has shown pumping and gas transfer capabilities that are more than sufficient to meet the needs of its intended clinical use. The P-PAL also exhibits low device-induced hemolysis and thus is ideal for long-term use. Future work includes in vivo evaluation of the P-PAL during both acute and chronic animal studies. Longterm (> 2 weeks) animal testing will be especially critical for the P-PAL considering the extended duration of its intended use. Incorporation of thromboresistant coatings to the bloodcontacting surfaces of the P-PAL is also under development. 29 
